阿托伐他汀序贯治疗对老年中、重度慢性肾病患者冠状动脉介入术后对比剂肾病的影响被引量：10

下载PDF

导出

摘要目的观察阿托伐他汀序贯治疗对老年中、重度慢性肾病(CKD)患者冠状动脉介入(PCI)术后对比剂肾病(CIN)是否具有预防作用。方法入选186例接受PCI治疗的老年中、重度CKD患者,随机分为阿托伐他汀组(96例)和对照组(90例),阿托伐他汀组术前予阿托伐他汀序贯治疗(术前12 h阿托伐他汀80 mg,术前2 h阿托伐他汀40 mg,术后40 mg/d),对照组术前及术后均予其他他汀常规治疗,观察术前、术后第1天、第2天及第3天血肌酐(SCr)、血浆胱抑素C(Cys C)的变化及CIN的发生率。结果 PCI术后对照组中SCr峰值、△SCr、Cys C峰值及△Cys C均显着高于阿托伐他汀组(P<0.05)。根据SCr标准的CIN,对照组20例(22.2%),阿托伐他汀组10例(10.4%),CIN的发生率对照组显著高于阿托伐他汀组(P<0.05)。根据Cys C标准的CIN,对照组28例(31.1%),阿托伐他汀组14例(14.6%),对照组中CIN的发病率明显高于阿托伐他汀组(P<0.01)。结论阿托伐他汀序贯治疗能够预防老年中、重度CKD患者PCI术对比剂应用后肾功能恶化。

作者陈晖李顺辉邓雨晴熊强珍

机构地区南昌大学第三附属医院心血管内一科

出处《中国老年学杂志》 CAS CSCD 北大核心 2016年第7期1690-1692,共3页 Chinese Journal of Gerontology

关键词阿托伐他汀冠状动脉介入慢性肾病对比剂肾病

分类号 R541.4 [医药卫生—心血管疾病]

引文网络
相关文献

参考文献18

1Cavusoglu E,Chhabra S,Marmur JD,et al.The prevention of contrast-induced nephropathy in patients undergoing percutaneous coronary Intervention〔J〕.Minerva Cardioangiol,2004;52(5):419-32.
2Cowburn PJ,Patel H,Pipes RR,et al.Contrast nephropathy post cardiac resynchronization therapy:an under-recognized complication with important morbidity〔J〕.Eur J Heart Fail,2005;7(5):899-903.
3Horl WH.Contrast induced nephropathy〔J〕.Wien Klin Wochenschr,2009;121(1-2):15-32.
4Laville M,Juillard L.Contrast-induced acute kidney injury:how should at-risk patients be identified and managed〔J〕?J Nephrol,2010;23(4):387-98.
5Patti G,Ricottini E,Nusca A,et al.Short-term,high-dose atorvastatin pretreatment to prevent contrast-induced nephropathy in patients with acute coronary syndromes undergoing percutaneous coronary intervention from the ARMYDA-CIN〔atorvastatin for reduction of myocardial damage during angioplasty contrast-induced nephropathy〕trial〔J〕.Am J Cardiol,2011;108(1):1-7.
6National Kidney Foundation.K/DOQI clinical practice guidelines for chronic kidney disease:evaluation,classification,and stratification〔J〕.Am J Kidney Dis,2002;39(2 Suppl 1):S1-266.
7Stacul F,van der Molen AJ,Reimer P,et al.Contrast induced nephropathy:updated ESUR contrast media safety committee guidelines〔J〕.Eur Radiol,2011;21(12):2527-41.
8Droppa M,Desch S,Blase P,et al.Impact of N-acetylcysteine on contrast-induced nephropathy defined bycystatin C in patients with ST-elevation myocardial infarction undergoing primary angioplasty〔J〕.Clin Res Cardiol,2011;100(11):1037-43.
9Nie B,Cheng WJ,Li YF,et al.A prospective,double-blind,randomized,controlled trial on the efficacy and cardiorenal safety of iodixanol vs.iopromide in patients with chronic kidney disease undergoing coronary angiography with or without percutaneous coronary intervention〔J〕.Catheter Cardiovasc Interv,2008;72(7):958-65.
10Mc Cullough PA,Adam A,Becker CR,et al.Risk prediction of contrastinduced nephropathy〔J〕.Am J Cardiol,2006;98(6A):27-36.

二级参考文献24

1许爱国,黄振文,郭攀,卢常青.阿托伐他汀对急性冠脉综合征患者炎性介质及临床预后的影响[J].郑州大学学报（医学版）,2006,41(4):699-701. 被引量：6
2缪绯,刘映峰,傅强,李志梁,李公信,吴宏超,徐琳.阿托伐他汀对外周血中树突状细胞成熟及免疫功能的影响[J].中国医科大学学报,2007,36(3):265-267. 被引量：4
3Toprak O.Risk markers for contrast induced nephropathy[J].Am J Med Sci,2007,334(4):283-290.
4Rihal CS,Textor SC,Grill DE,et al.Incidence and prognostic im-portance of acute renal failure after percutaneous coronary interven-tion[J].Circulation,2002,105(19):2259-2264.
5Lindsay J,Apple S,Pinnow EE,et al.Percutaneous coronary inter-vention associated nephro-pathy foreshadows increased risk of lateadverse events in patients with normal baseline serum creatinine[J].Catheter Cardiovasc Interv,2003,59(3):338-343.
6McCullough PA,Wolyn R,Rocher LL,et al.Acute renal failureafter coronary intervention:incidence,risk factors,and relationshipto mortality[J].Am J Med,1997,103(5):368-375.
7Bartholomew BA,Harjai KJ,Dukkipati S,et al.Impact of ne-phropathy after percutaneous coronary intervention and a method forrisk stratification[J].Am J Cardiol,2004,93(12):1515-1519.
8Mehran R,Aymong E,Nikolsky E,et al.A simple risk score forprediction of CIN after percutaneous coronary intervention:Develop-men and innitial Validation[J].J Am Coll Cardiol,2004,44(7):1393-1399.
9Maioli M,Toso A,Gallopin M,et al.Preprocedural score for risk ofcontrast-induced nephro-pathy in elective coronary angiography andintervention[J].J Cardiovasc Med,2010,11(6):444-449.
10Bachorzewska-Gajewska H,Malyszko J,Sitniewska E,et al.Couldneutrophil gelatinase asso-ciated lipocalin and cystatin C predict thedevelopment of contrast induced nephropathy after percutaneous cor-onary interventions in patients with stable angina and normal serumcreate-nine values[J].Kidney Blood Press Res,2007,30(6):408-4015.